OGN
NYSE · Pharmaceuticals
Organon & Co
$13.82
-0.01 (-0.07%)
Financial Highlights (FY 2026)
Revenue
6.26B
Net Income
188.45M
Gross Margin
53.3%
Profit Margin
3.0%
Rev Growth
+0.2%
D/E Ratio
11.49
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 53.3% | 53.3% | 28.3% | 28.3% |
| Operating Margin | 6.8% | 6.2% | 27.9% | 29.6% |
| Profit Margin | 3.0% | 2.9% | 28.0% | 28.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 6.26B | 6.25B | 515.23M | 479.67M |
| Gross Profit | 3.34B | 3.33B | 145.97M | 135.89M |
| Operating Income | 428.49M | 384.76M | 143.74M | 141.87M |
| Net Income | 188.45M | 169.22M | 144.40M | 138.60M |
| Gross Margin | 53.3% | 53.3% | 28.3% | 28.3% |
| Operating Margin | 6.8% | 6.2% | 27.9% | 29.6% |
| Profit Margin | 3.0% | 2.9% | 28.0% | 28.9% |
| Rev Growth | +0.2% | +0.2% | +11.5% | -9.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 1.67B | 1.67B | 937.97M | 935.09M |
| Total Equity | 145.44M | 145.44M | 1.31B | 1.37B |
| D/E Ratio | 11.49 | 11.49 | 0.71 | 0.68 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 585.54M | 554.99M | 186.20M | 184.13M |
| Free Cash Flow | — | — | 113.95M | 97.08M |